Jan Budczies
Jan Budczies
Professor of Bioinformatics, Institute of Pathology, University Hospital Heidelberg
Verified email at
Cited by
Cited by
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi
Breast cancer research and treatment 123, 725-731, 2010
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer
B Győrffy, P Surowiak, J Budczies, A Lánczky
PloS one 8 (12), e82241, 2013
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ...
PloS one 7 (12), e51862, 2012
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma …
A Warth, T Muley, M Meister, A Stenzinger, M Thomas, P Schirmacher, ...
Journal of clinical oncology 30 (13), 1438-1446, 2012
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression
M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ...
Cancer research 71 (9), 3236-3245, 2011
Mass spectrometry–based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors
C Denkert, J Budczies, T Kind, W Weichert, P Tablack, J Sehouli, ...
Cancer research 66 (22), 10795-10804, 2006
Tumor mutational burden as a predictive biomarker in solid tumors
D Sha, Z Jin, J Budczies, K Kluck, A Stenzinger, FA Sinicrope
Cancer discovery 10 (12), 1808-1825, 2020
Metabolite profiling of human colon carcinoma–deregulation of TCA cycle and amino acid turnover
C Denkert, J Budczies, W Weichert, G Wohlgemuth, M Scholz, T Kind, ...
Molecular cancer 7 (1), 1-15, 2008
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, BM Müller, H Eidtmann, WD Schmitt, W Eiermann, ...
Annals of oncology 24 (11), 2786-2793, 2013
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
S Darb-Esfahani, CA Kunze, H Kulbe, J Sehouli, S Wienert, J Lindner, ...
Oncotarget 7 (2), 1486, 2016
The landscape of metastatic progression patterns across major human cancers
J Budczies, M von Winterfeld, F Klauschen, M Bockmayr, JK Lennerz, ...
Oncotarget 6 (1), 570, 2015
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
C Denkert, S Wienert, A Poterie, S Loibl, J Budczies, S Badve, ...
Modern Pathology 29 (10), 1155-1164, 2016
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of …
BM Müller, L Jana, A Kasajima, A Lehmann, J Prinzler, J Budczies, ...
BMC cancer 13 (1), 1-8, 2013
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells
N Eckstein, K Servan, B Hildebrandt, A Pölitz, G Jonquières, ...
Cancer research 69 (7), 2996-3003, 2009
Strategies for developing Ki67 as a useful biomarker in breast cancer
C Denkert, J Budczies, G von Minckwitz, S Wienert, S Loibl, F Klauschen
The Breast 24, S67-S72, 2015
A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer
Z Mihály, M Kormos, A Lánczky, M Dank, J Budczies, MA Szász, B Győrffy
Breast cancer research and treatment 140, 219-232, 2013
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism
J Budczies, SF Brockmöller, BM Müller, DK Barupal, C Richter-Ehrenstein, ...
Journal of proteomics 94, 279-288, 2013
Heterogeneous expression of Wnt/β‐catenin target genes within colorectal cancer
F Hlubek, T Brabletz, J Budczies, S Pfeiffer, A Jung, T Kirchner
International journal of cancer 121 (9), 1941-1948, 2007
The system can't perform the operation now. Try again later.
Articles 1–20